| 1 |
26171197 | Phase II trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer. | 2015 Jul |
1 |
| 2 |
23510862 | Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. | 2014 Jan |
1 |
| 3 |
24769540 | The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review. | 2014 Apr 28 |
1 |
| 4 |
18367123 | Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate. | 2009 Jan-Feb |
2 |
| 5 |
19167733 | A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. | 2009 Mar |
3 |
| 6 |
18070197 | Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. | 2008 Apr |
1 |
| 7 |
15226321 | Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. | 2004 Jul 1 |
2 |
| 8 |
11448901 | A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. | 2001 Jul |
2 |
| 9 |
10357564 | Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. | 1999 |
3 |